Subtype
Benign Musculoskeletal Neoplasm
CI-CAN-00000516Explore in graph →
Non-malignant48 active trials5 evidence items
- NCIt
- C166356
Loading cancer entity…
Subtype
CI-CAN-00000516Explore in graph →
Clinical trials
465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04550429 | Uterine Filling Pressure in Hysteroscopy | terminated | N/A | 35 | Northwestern UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05017246 | Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy | terminated | Phase 2 | 110 | Washington University School of MedicineOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT03194646 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 6) | terminated | Phase 3 | 1,272 | BayerINDUSTRY | 13 | Jul 28, 2025 | clinicaltrials |
| NCT06106633 | Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization(PEDD-UFE) | terminated | N/A | 3 | Massachusetts General HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT03118037 | Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry(SAGE) | terminated | — | 182 | GynesonicsINDUSTRY | 3 | Dec 16, 2024 | clinicaltrials |
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | terminated | Phase 3 | 766 | BayerINDUSTRY | 23 | Oct 18, 2024 | clinicaltrials |
| NCT04849858 | Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures | terminated | Phase 3 | 13 | University of California, IrvineOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT04004884 | Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)(LISA) | terminated | — | 30 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT02940041 | Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors(CERTUM) | terminated | — | 15 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 0 | Dec 26, 2023 | clinicaltrials |
| NCT02209545 | Misoprostol for Reduction of Blood Loss During Fibroid Surgery | terminated | Phase 4 | 47 | Northwestern UniversityOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT00001850 | Evaluation of Women With Endocrine and Reproductive-Related Conditions | terminated | — | 833 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | May 25, 2023 | clinicaltrials |
| NCT03400943 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) | terminated | Phase 3 | 93 | BayerINDUSTRY | 9 | May 3, 2023 | clinicaltrials |
| NCT04073485 | Microwave Ablation for Uterine Fibroids | terminated | N/A | 6 | Chinese University of Hong KongOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT02654340 | Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)(TuScCom) | terminated | — | 20 | CENTOGENE GmbH RostockINDUSTRY | 8 | Feb 10, 2023 | clinicaltrials |
| NCT03442985 | An Efficacy and Safety Study of Palovarotene for the Treatment of MO(MO-Ped) | terminated | Phase 2 | 193 | Clementia Pharmaceuticals Inc.INDUSTRY | 12 | Aug 1, 2022 | clinicaltrials |
| NCT03400956 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) | terminated | Phase 3 | 103 | BayerINDUSTRY | 5 | Jun 30, 2022 | clinicaltrials |
| NCT02739555 | Zoledronic Acid Compared to Percutaneous Treatment in Osteoid Osteoma(BISPHOO) | terminated | Phase 3 | 15 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT00232713 | Uterine Fibroid Pregnancy Registry | terminated | — | 2,360 | Syneos HealthOTHER | 0 | Jul 1, 2021 | clinicaltrials |
| NCT03342859 | Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned | terminated | Phase 1 | 10 | BayerINDUSTRY | 1 | Jan 6, 2021 | clinicaltrials |
| NCT02425878 | Ulipristal Acetate 10 mg and Asisted Reproduction | terminated | Phase 3 | 2 | Instituto Valenciano de Infertilidad, IVI VALENCIAOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT01280045 | Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy | terminated | N/A | 5 | University of Sao PauloOTHER | 0 | Aug 13, 2020 | clinicaltrials |
| NCT01738724 | Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin | terminated | Phase 4 | 14 | University of Sao PauloOTHER | 0 | Aug 13, 2020 | clinicaltrials |
| NCT04132349 | Ulipristal Acetate in Symptomatic Uterine Fibroid | terminated | Phase 4 | 25 | Mỹ Đức HospitalOTHER | 1 | Apr 13, 2020 | clinicaltrials |
| NCT02825719 | Ulipristal Use in Chinese Population | terminated | Phase 4 | 31 | Queen Mary Hospital, Hong KongOTHER | 1 | Apr 9, 2020 | clinicaltrials |
| NCT01834703 | Uterine Artery Embolization(UAE) Versus High-Intensity-Focused-Ultrasound(HIFU) for Treatment of Uterine Fibroids | terminated | N/A | 85 | Chinese University of Hong KongOTHER | 1 | Aug 30, 2019 | clinicaltrials |
| NCT03210324 | A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy | terminated | Phase 4 | 434 | China Resources Zizhu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 7, 2019 | clinicaltrials |
| NCT02811159 | An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids | terminated | Phase 2 | 20 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT02879058 | Intraoperative Ultrasound in Laparoscopic or Robotic Myomectomy Patients | terminated | N/A | 140 | The Cleveland ClinicOTHER | 1 | Mar 4, 2019 | clinicaltrials |
| NCT00730886 | ExAblate Treatment of Uterine Fibroids for Fertility Enhancement | terminated | N/A | 2 | InSightecINDUSTRY | 1 | Aug 15, 2018 | clinicaltrials |
| NCT00710346 | Establishment of Fibroid Tissue Bank | terminated | — | 43 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Jun 1, 2018 | clinicaltrials |
| NCT01842789 | Post Market Evaluation of Acessa With TAG(TAG) | terminated | N/A | 18 | Acessa Health, Inc.INDUSTRY | 1 | Aug 18, 2017 | clinicaltrials |
| NCT02633254 | Targeted Vessel Ablation of Type 3 Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound | terminated | N/A | 6 | UMC UtrechtOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01504308 | Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids(SOFIA) | terminated | Phase 2 / Phase 3 | 49 | Philips HealthcareINDUSTRY | 3 | Apr 5, 2017 | clinicaltrials |
| NCT01581905 | Study of Conventional Laparoscopic Hysterectomy Versus Robot-Assisted Laparoscopic Hysterectomy at a Teaching Institution | terminated | N/A | 98 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT01555073 | Preemptive Analgesia Following Uterine Artery Embolization | terminated | Phase 4 | 23 | Northwestern UniversityOTHER | 1 | Jul 28, 2016 | clinicaltrials |
| NCT00219778 | A Study on the Efficacy of 10 mg Oral Mifepristone for the Treatment of Symptomatic Uterine Leiomyomas | terminated | Phase 2 | 20 | Poitiers University HospitalOTHER | 1 | Apr 6, 2016 | clinicaltrials |
| NCT01675011 | Embozene Microspheres for Uterine Fibroid Embolization (UFE) | terminated | N/A | 4 | Boston Scientific CorporationINDUSTRY | 1 | Mar 11, 2016 | clinicaltrials |
| NCT01226290 | Fibroid Ablation Study(FAST-EU) | terminated | N/A | 51 | GynesonicsINDUSTRY | 3 | Apr 2, 2015 | clinicaltrials |
| NCT01539187 | Fibroid Ablation Study - Large Fibroids(FAST-L) | terminated | N/A | 6 | GynesonicsINDUSTRY | 3 | Mar 17, 2015 | clinicaltrials |
| NCT01998854 | Observational Prospective Study on Patients With Symptomatic Uterine Fibroids Treated With VizAblate® Intrauterine-ultrasound Guided RF Ablation | terminated | — | 4 | GynesonicsINDUSTRY | 1 | Mar 11, 2015 | clinicaltrials |
| NCT01786226 | Mifepristone to Treat Uterine Fibroids | terminated | Phase 2 / Phase 3 | 220 | Mediterranea Medica S. L.OTHER | 1 | Sep 5, 2014 | clinicaltrials |
| NCT00958893 | An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext | terminated | Phase 2 | 4 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 25, 2014 | clinicaltrials |
| NCT00683917 | Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids | terminated | Phase 2 | 10 | Repros Therapeutics Inc.INDUSTRY | 2 | Aug 21, 2014 | clinicaltrials |
| NCT00702702 | Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 56 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00735553 | Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 77 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00737282 | Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids | terminated | Phase 3 | 175 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00785356 | Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 8 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00853567 | Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 71 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT01069120 | Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 27 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Apr 30, 2026source: clinicaltrials